Buchumschlag

PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma

AbstractBackground:Targeted therapies with BRAF plus MEK inhibitors (BRAFi; MEKi)represent the major treatment strategy for patients with BRAF-mutated metastatic melanoma(MM). Previous analyses suggested a correlation between programmed death-ligand 1 (PD-L1)expression in tumour tissues and the outc...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Schaper-Gerhardt, Katrin (VerfasserIn) , Utikal, Jochen (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2018
In: European journal of cancer
Year: 2017, Jahrgang: 88, Pages: 67-76
ISSN:1879-0852
DOI:10.1016/j.ejca.2017.10.026
Online-Zugang:Verlag, Volltext: https://doi.org/10.1016/j.ejca.2017.10.026
Volltext
Verfasserangaben:Katrin Schaper-Gerhardt, Steven Okoyea, Rudolf Herbst, Jens Ulrich, Patrick Terheyen, Claudia Pfö̈hler, Jochen S. Utikal, Alexander Kreuter, Peter Mohr, Edgar Dippel, Imke Satzger, Antje Sucker, Dirk Schadendorf, Selma Ugurel, Ralf Gutzmera
Beschreibung
Zusammenfassung:AbstractBackground:Targeted therapies with BRAF plus MEK inhibitors (BRAFi; MEKi)represent the major treatment strategy for patients with BRAF-mutated metastatic melanoma(MM). Previous analyses suggested a correlation between programmed death-ligand 1 (PD-L1)expression in tumour tissues and the outcome of targeted therapies. This study investigatedPD-L1 as a potential predictive biomarker of BRAFi-based targeted therapies in MM patients
Beschreibung:Gesehen am 28.05.2019
Available online 28 November 2017
Beschreibung:Online Resource
ISSN:1879-0852
DOI:10.1016/j.ejca.2017.10.026

Ähnliche Einträge